Literature DB >> 19687404

Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.

Beatriz Godoi Cavalheiro1, Consuelo Rodrigues Junqueira, Lenine Garcia Brandão.   

Abstract

OBJECTIVES: To develop an index for the ratio of metalloproteinase 2 (MMP-2) to its tissue inhibitor (TIMP-2) in immunostained medullary thyroid carcinoma specimens and to correlate it with clinical and pathologic prognostic factors. Metalloproteinases, enzymes related to the degradation of the extracellular matrix, take part in carcinogenesis and have been associated with the prognosis of neoplasias. Nevertheless, medullary carcinoma is rarely considered in research analysis. Researchers tend to favor the ratio of enzymes to their inhibitors over the absolute concentrations of these enzymes.
DESIGN: Retrospective study of surgical samples.
SETTING: Head and Neck Surgery and Endocrinology Departments, Universidade de São Paulo Medical School Hospital. PATIENTS: Surgical specimens from 33 patients who had been observed for a mean of 76.8 months (range, 4-201 months) were immunohistochemically stained for MMP-2 and TIMP-2. Only patients whose clinical and pathologic data were complete and whose specimens were preserved were included in the study. MAIN OUTCOME MEASURES: The ratio between the expressions of MMP-2 and TIMP-2 was based on a staining index (immunostaining extent and intensity) of each of the markers.
RESULTS: Proportionally large expressions of TIMP-2 over MMP-2 correlated with low occurrences of positive findings on initial cervical examination for the presence of thyroid nodules and/or lymphadenopathy (P = .02) and cervical lymph node metastases (P < .001), conditions correlated with prognosis. A correlation with cure at the end of follow-up (P = .01) was also observed. (P< .05 was considered statistically significant.)
CONCLUSION: The ratio of MMP-2 to TIMP-2 expression is an additional and novel prognostic predictor of the outcome of medullary carcinoma treated surgically.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687404     DOI: 10.1001/archoto.2009.92

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  1 in total

1.  Expression of HIF-1α in medullary thyroid cancer identifies a subgroup with poor prognosis.

Authors:  Lutske Lodewijk; Paul van Diest; Petra van der Groep; Natalie Ter Hoeve; Abbey Schepers; Johannes Morreau; Johannes Bonenkamp; Adriana van Engen-van Grunsven; Schelto Kruijff; Bettien van Hemel; Thera Links; Els Nieveen van Dijkum; Susanne van Eeden; Gerlof Valk; Inne Borel Rinkes; Menno Vriens
Journal:  Oncotarget       Date:  2017-04-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.